Is hypoglycaemia a modifiable patient risk in type 2 diabetes: A pooled analysis of insulin glargine 300 U/mL (Gla-300) vs 100U/mL (Gla-100) trials?

被引：0

作者：

Zhang, Q. ^{[1
]}

Rosenstock, J. ^{[2
]}

Gerrits, C. ^{[3
]}

Liao, L. ^{[3
]}

Chew, P. ^{[3
]}

机构：

[1] Rutgers State Univ, Piscataway, NJ USA

[2] Dallas Diabet & Endocrine Ctr, Dallas, TX USA

[3] Sanofi, Bridgewater, MA USA

来源：

DIABETOLOGIA | 2015年 / 58卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

974

引用

页码：S472 / S472

页数：1

共 50 条

[31] Comparative Effectiveness of Insulin Glargine 300 U/mL (Gla-300) and Insulin Degludec 100 U/mL (iDeg-100) in Insulin-Nave Type 2 Diabetes Adults: RESTORE-2 Real-World Study
Fadini, Gian Paolo
Buzzetti, Raffaella
Nicolucci, Antonio
Rossi, Maria Chiara
Larosa, Monica
Cucinotta, Domenico
[J]. DIABETES, 2021, 70
[32] A COST ANALYSIS FOR MACROVASCULAR EVENTS, COMPARISON OF GLARGINE 300U/ML (GLA-300) AND DEGLUDEC 100U/ML (IDEG-100) IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS IN OLDER POPULATION OR RENAL IMPAIRMENT INDIVIDUALS IN LATIN AMERICA
Londono, S.
Garcia, W.
Salamanca, C.
Silva, L.
Santos, V
Upegui, A.
[J]. VALUE IN HEALTH, 2023, 26 (12) : S113 - S113
[33] COST-UTILITY EVALUATION OF INSULIN GLARGINE 300 (GLA-300) VERSUS INSULIN GLARGINE 100 (GLA-100) IN PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM)
Delgado, M.
Rubio, M.
Gasche, D.
Fournier, M.
Monereo, S.
[J]. VALUE IN HEALTH, 2016, 19 (07) : A675 - A675
[34] Efficacy and Safety of Insulin Glargine 300 Units/mL (Gla-300) Versus Insulin Glargine 100 Units/mL (Gla-100) in Children and Adolescents (6-17 years) With Type 1 Diabetes: Results of the EDITION JUNIOR Randomized Controlled Trial
Danne, Thomas
Tamborlane, William V.
Malievsky, Oleg A.
Franco, Denise R.
Kawamura, Tomoyuki
Demissie, Marek
Niemoeller, Elisabeth
Goyeau, Harmonie
Wardecki, Marek
Battelino, Tadej
[J]. DIABETES CARE, 2020, 43 (07) : 1512 - 1519
[35] Clinical Perspectives from the BEGIN and EDITION Longer-Acting Insulin Programs: Trial-Level Meta-analyses Outcomes with either Degludec (IDeg) or Glargine 300 U/mL (Gla-300) vs. Glargine 100 U/mL (Gla-100) in T2DM
Rosenstock, Julio
Ritzel, Robert A.
Chevalier, Soazig
Balkau, Beverley
Roussel, Ronan
[J]. DIABETES, 2016, 65 : A249 - A249
[36] The Use of Supportive Tools and Education Enables Self-Titration with Insulin Glargine 300 (Gla-300) or 100 U/mL (Gla-100) in People with Type 2 Diabetes (T2DM)-Results from TAKE CONTROL, INNOVATE, and AUTOMATIX
Kvapil, Milan
Bonnemaire, Mireille
Goyeau, Harmonie
Papanas, Nikolaos
Popescu, Luiza
Schultes, Bernd
Sieber, Jochen
Duvnjak, Lea
[J]. DIABETES, 2018, 67
[37] Improved Glycemic Control with Insulin Glargine 300 U/mL vs. Glargine 100 U/mL in Type 1 Diabetes
Paola, Lucidi
Cioli, Patrizia
Candeloro, Paola
Andreoli, Anna Marinelli
Bolli, Geremia B.
Fanelli, Carmine G.
Porcellati, Francesca
[J]. DIABETES, 2020, 69
[38] COST-EFFECTIVENESS ANALYSIS OF ONCE- DAILY INSULIN GLARGINE 300 U/ML (GLA-300) VS INSULIN DEGLUDEC (IDEG-100) USING THE BRAVO DIABETES MODEL
Shao, H.
Shi, L.
Fonseca, V
Alsaleh, Omar A. J.
Gill, J.
Nicholls, C.
[J]. VALUE IN HEALTH, 2022, 25 (01) : S102 - S102
[39] Gender differences in achieving glycaemic control in patients with type 2 diabetes initiated on insulin glargine 300 U/ml (Gla-300): the European REALI pooled database
Bonnemaire, M.
Bonadonna, R.
Freemantle, N.
Mauricio, D.
Muller-Wieland, D.
Bigot, G.
Mauquois, C.
Ciocca, A.
Gourdy, P.
[J]. DIABETOLOGIA, 2019, 62 : S439 - S439
[40] Similar or Lower Severe Hypoglycemia Rates with Insulin Glargine 300 U/mL (Gla-300) vs. Glargine 100 U/mL (Gla-100), Detemir (IDet), and Insulin Degludec (IDeg) in 112,626 People with Type 2 Diabetes Mellitus (T2DM)-Predictive Modeling Using Real-World Data-Lightning
Pettus, Jeremy
Bailey, Timothy S.
Zhou, Fang L.
Bosnyak, Zsolt
Westerbacka, Jukka
Berria, Rachele
Jimenez, Javier
Hramiak, Irene
Meneghini, Luigi
[J]. DIABETES, 2018, 67

← 1 2 3 4 5 →